Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy.

Luis Manso,Eva Ciruelos,Manuel Codes,J de la Haba,A. Galan,J M Baena,Ana Jaén,Miquel Gil,A. Murias,Isabel Blancas,Encarnación González,D. Perez,J. L. Bayo,J. R. Mel,E. García Martínez,Ricardo Cubedo,Javier Salvador

Clinical value of circulating epithelial tumor cells and circulating endothelial cells (CTCs/CECs) in patients with HER2-negative recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) as first-line therapy.

2011

Luis Manso
Eva Ciruelos
Manuel Codes
J de la Haba
A. Galan
J M Baena
Ana Jaén
Miquel Gil
A. Murias
Isabel Blancas
Encarnación González
D. Perez
J. L. Bayo
J. R. Mel
E. García Martínez
Ricardo Cubedo
Javier Salvador

e21105 Background: Worse prognosis of the presence of CTCs in peripheral blood has been demonstrated in MBC and have potencial to influence the clinical management for pts. Bevacizumab (B) in combi...

Keywords:

Bevacizumab
Paclitaxel
HER2 negative
Oncology
Gemcitabine
Medicine
Internal medicine
Metastatic breast cancer
first line therapy
breast carcinoma
tumor cells
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations